Abstract:Introduction: Robust predictive measures for Type 2 diabetes (T2D) vascular complications to facilitate early intervention strategies are needed. Methods: Fasting plasma from 363 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial participants (mean±SD) age: 61.3±6.4 yrs, 5.6±5.4 yrs T2D, HbA1c: 6.7±1.2% (49.7±13.4 mmol/mol), were collected at baseline and stored (-80°C) until quantitative proteomics analysis of tryptic peptides. Protein signatures associated with future micro- or macrovascular complications (100 and 54 subjects, respectively) were identified using a random forest approach, adjusted for treatment allocation. Exhaustive search using logistic regression was then carried out to optimise models. Pathway analysis was carried out using the NIH functional annotation tool, DAVID Bioinformatics. Resources. Results: Fifty targets were selected: 14 were associated with microvascular, 13 with macrovascular complications and 23 were common for both. Pathway analysis revealed six main pathways: cholesterol metabolism, platelet activation, complement and coagulation, focal cell adhesion, actin cytoskeleton and hypertrophic cardiomyopathy. In logistic regression, the optimal model for prediction of microvascular complications with overall p<0.0001, AUC=0.74 contained Cadherin-5, Clusterin, Ceruloplasmin, Glutathione peroxidase 3 and Inter-alpha-trypsin inhibitor heavy chain H3. For macrovascular complications the model contained Zinc-alpha-2-glycoprotein and Coagulation factor V (p<0.0001, AUC=0.72). For any micro- or macro-vascular complications, the model contained Cholinesterase, Ceruloplasmin, Mannose-binding protein C and Coagulation factor V (p<0.0001, AUC=0.70). Conclusion: Proteomic signatures represent a promising first step towards identifying protein signatures associated with T2D complications. Future research will aim at finding therapeutic targets in the metabolic pathways identified by those proteins. Disclosure H. Francis: None. A.S. Januszewski: None. A.A. Hardikar: None. M.V. Joglekar: None. D. Sullivan: None. A. Jenkins: Research Support; Abbott, Viatris Inc. Advisory Panel; Abbott. Research Support; Medtronic. Board Member; Insulin for Life. Research Support; Leona M. and Harry B. Helmsley Charitable Trust, Juvenile Diabetes Research Foundation (JDRF), Jaeb Center for Health Research, National Institutes of Health, National Health and Medical Research Council Australia. M.P. Molloy: None. A.C. Keech: Research Support; Abbott, Amgen Inc., Bayer Inc., Kowa Company, Ltd., Mylan. Speaker's Bureau; Novartis Pharmaceuticals Corporation. Research Support; Novartis Pharmaceuticals Corporation, Sanofi, Viatris Inc. Funding National Health and Medical Research Council (GNT1147897)

Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.

Association of MTHFR C677T Polymorphism and Type 2 Diabetes Mellitus (T2DM) Susceptibility

Association of matrix metalloproteinase and their tissue inhibitors gene polymorphisms with progression of angiographic coronary plaque in type 2 diabetic patients

Association between mannose-binding lectin 2 gene and protein kinase C-β1 gene polymorphisms and type 2 diabetic macrovascular complications in northern Chinese Han population

Association analysis of MTHFR (rs1801133 and rs1801131) gene polymorphism towards the development of type 2 diabetes mellitus in Dali area population from Yunnan Province, China

[Association between mannose-binding lectin 2 gene and protein kinase C-beta 1 gene polymorphisms and type 2 diabetic macrovascular complications in northern Chinese Han population]

Association Study to Evaluate Tfpi Gene in Cad in Han Chinese

The MTHFR C677T/A1298C polymorphism is associated with increased risk of microangiopathy in type 2 diabetes mellitus: A systematic review and meta-analysis

Association of Angiotensin I Converting Enzyme, Angiotensin II Type 1 Receptor and Angiotensin I Converting Enzyme 2 Gene Polymorphisms with the Dyslipidemia in Type 2 Diabetic Patients of Chinese Han Origin

The Correlation Analysis of Venous Thromboembolism and Acute Myocardial Infarction with the Levels and Polymorphisms of Coagulation and Anticoagulation Factors.

The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy

Polymorphisms in the Vascular Endothelial Growth Factor Gene and the Risk of Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes

Relationship between circulating thrombospondin‐1 messenger ribonucleic acid and microribonucleic acid‐194 levels in Chinese patients with type 2 diabetic kidney disease: The outcomes of a case–control study

Determination of Vasculopathy-Related Indexes in Patients with Type 2 Diabetes Mellitus and Its Clinical Significance

Clinical study of the association between tissue factor pathway inhibitor 2 (TFPI-2) gene polymorphisms and acute coronary syndrome

Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia

Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity

The associations between single nucleotide polymorphisms and diabetic retinopathy risk: an umbrella review

1799-LB: Identification of Proteomics Signature for Vascular Complications in Type 2 Diabetes

Abstract TP159: The Effect Of Diabetes Mellitus On Thrombus Composition In Patients With Stroke

ANGPTL8 Gene Polymorphism rs2278426 Is Related to Carotid Intima–Media Thickness in T2DM